Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 10/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 4/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802004 | 0.81 | ALPL (0.47) | ALPLDGAT1MEN1NPC1RAB9A | |
| SCHEMBL21802036 | 0.81 | ALPL (0.47) | ALPLDGAT1MEN1NPC1RAB9A | |
| SCHEMBL21801941 | 0.78 | ALPL (0.51) | ALPL | |
| SCHEMBL21802106 | 0.78 | ALPL (0.51) | ALPLDGAT1 | |
| SCHEMBL30538759 | 0.78 | ALPL (0.52) | ALPL | |
| SCHEMBL21801979 | 0.78 | ALPL (0.52) | ALPL | |
| SCHEMBL21802108 | 0.78 | ALPL (0.52) | ALPL | |
| SCHEMBL21802118 | 0.78 | ALPL (0.51) | ALPLDGAT1 | |
| SCHEMBL21801978 | 0.77 | ALPL (0.52) | ALPL | |
| SCHEMBL22823941 | 0.76 | ALPL (0.44) | ALPLDGAT1MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | ALPI, ASAH2, STS | ALPL 7/4885DGAT1 1885/4885MEN1 2570/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | ALPL 5/4885DGAT1 1040/4885MEN1 2626/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | ALPL 7/4885DGAT1 1885/4885MEN1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.